Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.7)
Index Copernicus  – 161.11; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 1, January, p. 11–18

doi: 10.17219/acem/76263

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Expression rate of myogenic regulatory factors and muscle growth factor after botulinum toxin A injection in the right masseter muscle of dystrophin deficient (mdx) mice

Ute U. Botzenhart1,C,D,E,F, Ricarda Gerlach1,B, Tomasz Gredes1,C,D,E,F, Ines Rentzsch2,B, Tomasz Gedrange1,F, Christiane Kunert-Keil1,A,B,C,D,E,F

1 Department of Orthodontics, Carl Gustav Carus Campus, Technische Universität Dresden, Germany

2 Department of Anesthesiology and Intensive Care Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany

Abstract

Background. The mdx mouse, the most approved animal model for basic research in Duchenne muscular dystrophy (DMD), has the ability to compensate muscle degeneration by regeneration process, which is obvious at approx. 3 months of age. Hence, this mouse model is only temporarily suitable to proof craniofacial changes which are usually evident in humans with the progression of the disease.
Objectives. The purpose of our study was to examine the impact of botulinum toxin A (BTX-A) in influencing muscle regeneration in the masticatory muscles of healthy and mdx mice.
Material and Methods. Chemo-denervation of the right masseter muscle was induced in 100-day-old, healthy and dystrophic mice by a specific intramuscular BTX-A injection. Gene expression and protein content of myogenic regulatory factors and muscle growth factor (MyoD1, myogenin and myostatin) in the right and left masseter, temporal and the tongue muscle were determined 4 and 21 days after injection, respectively, using quantitative reverse transcription polymerase chain reaction (qRT-PCR) and western blot technique.
Results. The 4 day and 21 day interval proved significant but varying changes of mRNA expression in both control and mdx mice. At the protein level, myogenin expression was increased in the temporal and masseter muscle on the injection side in controls, whereas dystrophic mice showed the same effect for MyoD1 expression. Additionally, increased protein expression of all studied genes could be found in dystrophic mice compared to controls, except the left temporal and the tongue muscle.
Conclusion. Muscle regeneration is not constant in BTX-A injected mdx masticatory muscles, presumably due to the already exhausted capacity or functional loss of satellite cells caused by dystrophin deficiency, and, therefore, disturbed regeneration potential of myofibrils. Botulinum toxin A injection cannot fully break down regulatory processes at molecular level in 100-day-old mdx mice. Further investigations are necessary to fully understand the regeneration process following BTX-A injection into dystrophic muscles.

Key words

myostatin, BTX-A, MyoD1, myogenin, mdx mice

References (40)

  1. Ciciliot S, Rossi AC, Dyar KA, Blaauw B, Schiaffino S. Muscle type and fiber type specificity in muscle wasting. Int J Biochem Cell Biol. 2013;45(10):2191–2199.
  2. Zanou N, Gailly P. Skeletal muscle hypertrophy and regeneration: Interplay between the myogenic regulatory factors (MRFs) and insulin-like growth factors (IGFs) pathways. Cell Mol Life Sci. 2013;70(21):4117–4130.
  3. Flynn JM, Meadows E, Fiorotto M, Klein WH. Myogenin regulates exercise capacity and skeletal muscle metabolism in the adult mouse. PloS One. 2010;5(10):e13535.
  4. Megeney LA, Kablar B, Garrett K, Anderson JE, Rudnicki MA. MyoD is required for myogenic stem cell function in adult skeletal muscle. Genes Dev. 1996;10(10):1173–1183.
  5. McCroskery S, Thomas M, Platt L, et al. Improved muscle healing through enhanced regeneration and reduced fibrosis in myostatin-null mice. J Cell Sci. 2005;118(Pt 15):3531–3541.
  6. Lepper C, Partridge TA, Fan CM. An absolute requirement for Pax7-positive satellite cells in acute injury-induced skeletal muscle regeneration. Development. 2011;138(17):3639–3646.
  7. Morgan JE, Zammit PS. Direct effects of the pathogenic mutation on satellite cell function in muscular dystrophy. Exp Cell Res. 2010;316(18):3100–3108.
  8. Eckardt L, Harzer W. Facial structure and functional findings in patients with progressive muscular dystrophy (Duchenne). Am J Orthod Dentofacial Orthop. 1996;110(2):185–190.
  9. Pichavant C, Pavlath GK. Incidence and severity of myofiber branching with regeneration and aging. Skelet Muscle. 2014;4:9.
  10. Bulfield G, Siller WG, Wight PA, Moore KJ. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci U S A. 1984;81(4):1189–1192.
  11. Heslop L, Morgan JE, Partridge TA. Evidence for a myogenic stem cell that is exhausted in dystrophic muscle. J Cell Sci. 2000;113(Pt 12):2299–2308.
  12. Hirai Y. Clostridium botulinum and botulinum neurotoxin [in Japanese]. Brain Nerve. 2011;63(7):755–761.
  13. Awan KH. The therapeutic usage of botulinum toxin (Botox) in non-cosmetic head and neck conditions: An evidence based review. Saudi Pharm J. 2017;25(1):18–24.
  14. Pantano S, Montecucco C. The blockade of the neurotransmitter release apparatus by botulinum neurotoxins. Cell Mol Life Sci. 2014;71(5):793–811.
  15. Tarabal O, Caldero J, Ribera J, et al. Regulation of motoneuronal calcitonin gene-related peptide (CGRP) during axonal growth and neuromuscular synaptic plasticity induced by botulinum toxin in rats. Eur J Neurosci. 1996;8(4):829–836.
  16. Botzenhart UU, Wegenstein C, Todorov T, Kunert-Keil C. Influence of botulinum toxin A on the expression of adult myhc isoforms in the masticatory muscles in dystrophin-deficient mice (mdx-mice). Biomed Res Int. 2016;2016:7063093.
  17. Botzenhart UU, Vaal V, Rentzsch I, Gredes T, Gedrange T, Kunert-Keil C. Changes in caveolin-1, caveolin-3 and vascular endothelial growth factor (VEGF) expression and protein content after botulinum toxin A (BTX-A) injection in the right masseter muscle of dystrophin deficient (mdx-) mice. J Physiol Pharmacol. 2017;68(1):181–189.
  18. Baverstock H, Jeffery NS, Cobb SN. The morphology of the mouse masticatory musculature. J Anat. 2013;223(1):46–60.
  19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–408.
  20. Barros Maranhao J, de Oliveira Moreira D, Mauricio AF, et al. Changes in calsequestrin, TNF-alpha, TGF-beta and MyoD levels during the progression of skeletal muscle dystrophy in mdx mice: A comparative analysis of the quadriceps, diaphragm and intrinsic laryngeal muscles. Int J Clin Exp Pathol. 2015;96(5):285–293.
  21. Spassov A, Gredes T, Lehmann C, et al. Myogenic differentiation factor 1 and myogenin expression not elevated in regenerated masticatory muscles of dystrophic (mdx) mice. J Orofac Orthop. 2011;72(6):469–475.
  22. Hatade T, Takeuchi K, Fujita N, Arakawa T, Miki A. Effect of heat stress soon after muscle injury on the expression of MyoD and myogenin during regeneration process. J Musculoskelet Neuronal Interact. 2014;14(3):325–333.
  23. de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: Biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A. 1999;96(6):3200–3205.
  24. Bornemann A, Maier F, Kuschel R. Satellite cells as players and targets in normal and diseased muscle. Neuropediatrics. 1999;30(4):167–175.
  25. Duregotti E, Zanetti G, Scorzeto M, et al. Snake and spider toxins induce a rapid recovery of function of botulinum neurotoxin paralysed neuromuscular junction. Toxins. 2015;7(12):5322–5336.
  26. Ma J, Shen J, Lee CA, et al. Gene expression of nAChR, SNAP-25 and GAP-43 in skeletal muscles following botulinum toxin A injection: A study in rats. J Orthop Res. 2005;23(2):302–309.
  27. Shen J, Ma J, Elsaidi GA, et al. Gene expression of myogenic regulatory factors following intramuscular injection of botulinum A toxin in juvenile rats. Neurosci Lett. 2005;381(3):207–210.
  28. Ugalde I, Christiansen SP, McLoon LK. Botulinum toxin treatment of extraocular muscles in rabbits results in increased myofiber remodeling. Invest Ophthalmol Vis Sci. 2005;46(11):4114–4120.
  29. Cornelison DD, Olwin BB, Rudnicki MA, Wold BJ. MyoD–/– satellite cells in single-fiber culture are differentiation defective and MRF4 deficient. Dev Biol. 2000;224(2):122–137.
  30. Beilharz MW, Lareu RR, Garrett KL, Grounds MD, Fletcher S. Quantitation of muscle precursor cell activity in skeletal muscle by Northern analysis of MyoD and myogenin expression: Application to dystrophic (mdx) mouse muscle. Mol Cell Neurosci. 1992;3(4):326–331.
  31. Meadows E, Flynn JM, Klein WH. Myogenin regulates exercise capacity but is dispensable for skeletal muscle regeneration in adult mdx mice. PloS One. 2011;6(1):e16184.
  32. Moresi V, Williams AH, Meadows E, et al. Myogenin and class II HDACs control neurogenic muscle atrophy by inducing E3 ubiquitin ligases. Cell. 2010;143(1):35–45.
  33. Dumont NA, Wang YX, von Maltzahn J, et al. Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division. Nat Med. 2015;21(12):1455–1463.
  34. Tsuchida K. The role of myostatin and bone morphogenetic proteins in muscular disorders. Expert Opin Biol Ther. 2006;6(2):147–154.
  35. Wehling M, Cai B, Tidball JG. Modulation of myostatin expression during modified muscle use. FASEB J. 2000;14(1):103–110.
  36. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997;387(6628):83–90.
  37. Wagner KR, Liu X, Chang X, Allen RE. Muscle regeneration in the prolonged absence of myostatin. Proc Natl Acad Sci U S A. 2005;102(7):2519–2524.
  38. Tsuchida K. Myostatin inhibition by a follistatin-derived peptide ameliorates the pathophysiology of muscular dystrophy model mice. Acta Myol. 2008;27:14–18.
  39. Tsao J, Vernet DA, Gelfand R, et al. Myostatin genetic inactivation inhibits myogenesis by muscle-derived stem cells in vitro but not when implanted in the mdx mouse muscle. Stem Cell Res Ther. 2013;4(1):4.
  40. Abe S, Soejima M, Iwanuma O, et al. Expression of myostatin and follistatin in Mdx mice, an animal model for muscular dystrophy. Zoolog Sci. 2009;26(5):315–320.
© Wroclaw Medical University